Interventional Cardiology. Группа авторов

Introduction Predisposing factors Pathogenesis Clinical manifestations QOL and economic impact Diagnosis Treatment Non‐invasive study: venous reflux disease Non‐invasive study: chronic venous flow obstruction Non‐invasive study: muscle pump dysfunction References

      13  Index

      14  End User License Agreement

      List of Tables

      1 Chapter 1Table 1.1 Comparison of plaque characteristics evaluation.Table 1.2 Serologic markers of vulnerable plaque/patient.

      2 Chapter 2Table 2.1 Types of closure devices.

      3 Chapter 3Table 3.1 Common diagnostic and guide catheter shapes for TRA.Table 3.2 Complications of transradial access.

      4 Chapter 4Table 4.1 Angiographic projections and optimal visualization of left and rig...Table 4.2 Popular view combinations for diagnostic angiography with benefits...

      5 Chapter 5Table 5.1 Guide catheter inner lumen size by manufacturer and outer lumen si...Table 5.2 The advantages and disadvantages of smaller versus larger catheter...Table 5.3 Comparability of curve sizes for different shapes of left sided gu...Table 5.4 The selection of a guidewire depends on the characteristics requir...Table 5.5 Classification of guidewires.Table 5.6 List of commonly used ultra low profile PTCA balloon.

      6 Chapter 6Table 6.1 Three main types of outcome data are analyzed in contemporary stud...Table 6.2 Common measures of association and calculations.Table 6.3 Key components of sample size/power calculations.Table 6.4 Impact of incorrect sample size assumptions on study power.

      7 Chapter 9Table 9.1 Comparison of optical coherence tomography systems.

      8 Chapter 11Table 11.1 Optimal secondary prevention in stable coronary artery disease.Table 11.2 ESC Guideline indications for revascularization in patients with ...Table 11.3 ESC guidelines for the type of revascularization (CABG or PCI) in...

      9 Chapter 12Table 12.1 The GRACE and TIMI scores for assessing the prognosis of patients...Table 12.2 Guideline recommendations on pre‐ and periprocedural therapy for ...

      10 Chapter 13Table 13.1 Key large‐cohort clinical trials involving 1st and subsequent gen...Table 13.2 Fibrinolytic agents in STEMI [4].

      11 Chapter 14Table 14.1 SCAI Classification of cardiogenic shock.

      12 Chapter 15Table 15.1 Summary of the main trials comparing coronary artery by‐pass graf...

      13 Chapter 16Table 16.1 Randomized controlled studies comparing provisional SB stenting v...

      14 Chapter 17Table 17.1 Guideline recommendations for stable multivessel coronary artery ...Table 17.2 Guideline recommendations for STEMI patients with multivessel cor...Table 17.3 Revascularization strategies in patients with multivessel coronar...Table 17.4 SYNTAX score and SYNTAX‐based models for risk stratification in m...

      15 Chapter 21Table 21.1 Incidence of restenosis after first and new generation DES implan...Table 21.2 Predictors of restenosis.

      16 Chapter 22Table 22.1 Anatomic, hemodynamic and clinical criteria used to identify high...Table 22.2 Characteristics of common percutaneous mechanical circulatory sup...

      17 Chapter 26Table 26.1 National Heart, Lung and Blood Institute (NHLBI) classification s...Table 26.2 Modified Ellis classification of coronary perforations along with...Table 26.3 Risk factors for coronary perforation.

      18 Chapter 27Table 27.1 Common vascular complications grouped by type of vascular access....Table 27.2 Common vascular complications related to femoral artery access an...Table 27.3 Risk Factors for bleeding complications related to femoral artery...Table 27.4 Techniques to prevent femoral artery access complications and sup...Table 27.5 Commonly used vascular closure devices (VCD) and mechanisms of ac...Table 27.6 Incidence of various types of vascular complications after percut...

      19 Chapter 28Table 28.1 RIFLE e AKIN criteria for acute kidney injury [14,15].Table 28.2 Mechanisms of contrast‐associated acute kidney injury.Table 28.3 AKI biomarkers categories.Table 28.4 Check list for estimating the risk of CA‐AKI and prevention strat...

      20 Chapter 29Table 29.1 Radiologic dose indicators.Table 29.2 Procedural physician radiation management items.Table 29.3 Notification and substantial radiation dose level (SRDL) levels [...Table 29.4 Post‐procedure patient notification and follow‐up.

      21 Chapter 31Table 31.1 Mechanical properties of PtCr compared to stainless steel and CoC...Table 31.2 Selected CoCr‐EES clinical trials.Table 31.3 Summary of clinical trials of promus element.

      22 Chapter 32Table 32.1 Composition of platinum‐chromium (PtCr) compared with stainless s...Table 32.2 Mechanical properties of PtCr compared with stainless steel and C...Table 32.3 Summary of clinical trials of Synergy stent.

      23 Chapter 33Table 33.1 Characteristics of resolute onyx and other contemporary drug‐elut...Table 33.2 Key features of ZES.Table 33.3 Selected all‐comers RCT evaluating ZES.

      24 Chapter 34Table 34.1 Overview of clinical studies with the biosensor international bio...Table 34.2 Overview of completed clinical studies with the biosensor interna...Table 34.3 Overview of completed clinical studies with the nobori biolimus‐e...

      25 Chapter 35Table 35.1 The orsiro clinical program.Table 35.2 Absorbable